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High dose (HD) IL-2 treatment is a potent form of
immunotherapy that can induce durable complete
responses in a fraction of metastatic melanoma patients.
Its initial purpose was to activate the expansion and anti-
tumor responses of NK cells. However, the efficacy of
HD IL-2 in achieving this has been relatively limited due
to two main reasons. First, IL-2 preferentially expands
CD4+CD25+Foxp3+ T-regulatory cells (Tregs) constitu-
tively expressing the high affinity IL-2R consisting of
CD25 together with the IL-2Rb and the common gamma
chain rather than NK cells and effector T cells that are
mostly CD25-negative and express mostly the IL-2Rbg
lower affinity receptor. In particular, we found that a
highly suppressive CD25hi Treg subset expressing ICOS
expands the most in response to IL-2. Second, HD IL-2
can be highly toxic by causing vascular leak syndrome
due to a surge in pro-inflammatory cytokines and by its
indirect activation of CD25 expressing endothelial cells
facilitating NO release. Here, we characterized whether a
mutant form of IL-2 (F42K) that preferentially binds to
the lower affinity IL-2Rbg complex can be an alternative
to wild-type (WT) IL-2 therapy. We first tested the
effects of equivalent concentrations of WT IL-2 on
PBMC from healthy donors and melanoma patients for 6
or 14 days in vitro. F42K-treated PBMC produced much
lower pro-inflammatory cytokines such as IL-6, IL-1a
and IFN-g, and VEGF than WT IL-2. Importantly, F42K
selectively expanded NK cells with a decreased expansion
of ICOS+ Tregs. In comparison to treatment with WT
IL-2, F42K also induced increased NK cell activation by
up-regulating the NK activation markers NKp30, NKp44
and TIM-3, but not NKG2D, CD226 and inhibitory KIR
molecules such as CD158a and CD158b. F42K also
enhanced survival of these highly activated NK cells and
prevented apoptosis by inducing a higher expression of
Bcl2 than WT IL-2. Furthermore, F42K increased NK
cell cytotoxicity against breast cancer and melanoma cells
than WT IL-2 associated with TRAIL and granulysin up-
regulation in both CD56hi and cytotoxic CD16+CD56+
NK cell subsets. Using a hydrodynamic gene therapy
(HGT) approach, C57BL/6 mice treated with plasmids
encoding F42K had an earlier, more robust and persistent
NK cell expansion in vivo with a dramatic reduction in
the expansion of CD4+CD25+Foxp3+Tregs than WT
IL-2 plasmid therapy. Lastly, we found that F42K was
equally able to expand TILs from melanoma patients as
WT IL-2. Our results suggest that F42K has great poten-
tial as a non-toxic substitute for WT IL-2 as a cytokine
therapy for cancer by potently activating NK cells without
Treg expansion either as a monotherapy or in combina-
tion with other therapies such as adoptive cell therapy.
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